There is one ongoing phase II trial investigating the benefit of trametinib for treating LGGs and pNFs in NF1 individuals [31], and other reports on trametinib for treating NF1-related nervous system tumors have also been published in recent years [25,32,33,34,35,36,37,38,39,40]. Here, NF1 is linked to nervous system neoplasm.